Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator.~* Newly established diagnosis of WD by Leipzig-Score ≥ 4 documented by testing as outlined in 2012 European Association for the Study of the Liver Wilson Disease Clinical Practice Guidelines.~* NCC levels within or above the normal reference range (0.8 to 2.3 micromole).~* Willing to undergo 48 hour washout from current WD treatment~Exclusion Criteria:~* Treatment for greater than 24 months for WD with chelation therapy (for example, penicillamine, trientine hydrochloride) or zinc therapy.~* Decompensated hepatic cirrhosis.~* Model for End-Stage Liver Disease score \> 11.~* Modified Nazer score \> 6.~* Gastrointestinal bleed within past 6 months.~* Alanine aminotransferase \> 5 x upper limit of normal.~* Marked neurological disease requiring either nasogastric feeding or intensive in-patient medical care.~* Severe anemia with a hemoglobin \< 9 grams/deciliter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALXN1840 (Type: EXPERIMENTAL): Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).